One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Hit the road JAK: is there still hope left for TYK2 inhibition in IBD?
doi : 10.1093/ecco-jcc/jjaf088
Volume 19, Issue 6, June 2025
Histology in Inflammatory Bowel Disease: A Redundant Tool or a Valuable Prognostic Marker?
doi : 10.1093/ecco-jcc/jjaf064
Gene-Environment Interactions in Inflammatory Bowel Disease: A Systematic Review of Human Epidemiologic Studies
doi : 10.1093/ecco-jcc/jjaf061
Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease
doi : 10.1093/ecco-jcc/jjaf087
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)
doi : 10.1093/ecco-jcc/jjaf060
Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients
doi : 10.1093/ecco-jcc/jjaf076
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
doi : 10.1093/ecco-jcc/jjaf080
Risk of colectomy is decreasing among newly diagnosed Finnish ulcerative colitis patients
doi : 10.1093/ecco-jcc/jjaf081
Epithelial genetic muscarinic receptor 3 ablation induces sex-specific modulation of colonic intestinal progenitor cells and response to intestinal injury
doi : 10.1093/ecco-jcc/jjaf038
Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn’s disease via fibroblast-specific YAP/TAZ inhibition
doi : 10.1093/ecco-jcc/jjaf084
Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel disease
doi : 10.1093/ecco-jcc/jjaf082
Serum biomarkers of collagen remodeling are associated with intestinal fibrosis and differentiate stenotic from luminal Crohn’s disease patients: a pre- and post-resection longitudinal study
doi : 10.1093/ecco-jcc/jjaf085
The angiotensin receptor blocker, losartan, reduces inflammation and fibrosis, and prevents relapse of fibrosis after steroid-induced remission, in mice prone to Crohn’s disease-like ileitis
doi : 10.1093/ecco-jcc/jjaf083
Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease
doi : 10.1093/ecco-jcc/jjae178
Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort—an Epi-IBD cohort study
doi : 10.1093/ecco-jcc/jjaf089
Histologic and Endoscopic Findings Are Highly Correlated in a Prospective Cohort of Patients With Inflammatory Bowel Diseases
doi : 10.1093/ecco-jcc/jjae141
Cancer incidence in patients with ulcerative colitis naïve to or treated with thiopurine and targeted therapies—a cohort study 2007 to 2022 with comparison to the general population
doi : 10.1093/ecco-jcc/jjaf091
Spatial immune profiling of Crohn’s disease fistula carcinomas—defining a distinct cancer subtype
doi : 10.1093/ecco-jcc/jjaf086
Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy
doi : 10.1093/ecco-jcc/jjaf092
The effectiveness of second- and-third-line biologics in perianal Crohn’s disease—a multicenter propensity score-matched study
doi : 10.1093/ecco-jcc/jjaf099
Impact of immunomodulating medication on maternal Tdap vaccination-induced antibodies in infants
doi : 10.1093/ecco-jcc/jjaf090
ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment Response
doi : 10.1093/ecco-jcc/jjaf073
